<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952223</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-AFU 23 - UC-0160/1202</org_study_id>
    <secondary_id>2012-000566-38</secondary_id>
    <nct_id>NCT01952223</nct_id>
  </id_info>
  <brief_title>A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse</brief_title>
  <acronym>PEACE2</acronym>
  <official_title>A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic
      radiotherapy in combination with ADT-radiotherapy on clinical progression-free survival in
      patients with high-risk localized prostate cancer (with a stringent selection of patients
      with at least 2 high-risk features), in a 2 by 2 factorial trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients can be randomized via the TENALEA web site process that insure
      centralization of the randomization.

      Randomization will be performed according a 1:1:1:1 ratio. The randomization will be
      stratified (by minimization) according to the number of risk factors (2 vs.3), disease extent
      (pN- vs. pN+ vs. pNx) and the site.

      The minimization will be defined with a similar weight for all 3 stratification factors and a
      probability of assigning the treatment that minimize the imbalance equal to 80%.

      The main analysis of PFS will be event driven (&gt;247 events). It will likely be performed when
      the median follow-up is approximately 6 years, i.e. 4 years after the inclusion of the last
      patient (assuming an accrual of 4 years).

      A long-term analysis (allowing for robust PFS and OS data) will also be performed when the
      follow-up is approximately 10 years. Its exact timing will be discussed with the steering
      committee and the IDMC.

      An interim analysis of the primary endpoint is planned. This interim analysis will be
      performed at a 0.001 level (Peto) after 50% of the events i.e. 125 have occurred.

      For each comparison (CT comparison and pelvic RT comparison) the two PFS curves will be
      compared using the adjusted logrank test (bilateral test): adjusted logrank on pelvic RT for
      the CT comparison and on CT for the pelvic RT comparison. A multivariate analysis using the
      Cox model will also be used.

      An Independent Data Monitoring Committee (IDMC) composed of international experts (at least 2
      physicians and 1 statistician) will be selected.

      For safety purpose, the IDMC will meet after the inclusion of 20 patients (and then again
      after accrual of 50 patients) in the cabazitaxel and pelvic radiotherapy arm, to assess
      tolerance, (i.e. after the inclusion of approximately 80 and then 200 patients in the trial).
      Depending on the results of this feasibility phase and of any new relevant clinical results
      in such a population, the remaining patients (n=848) will be enrolled.

      During this second phase, the IDMC will then meet every two years approximately during
      accrual to carefully assess accrual rate and toxicity and examine the efficacy interim
      analysis results in the light of the results of similar trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">December 2032</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>prostate-specific antigen response at 3 months</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biochemical progression-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metastases-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local relapse-free survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate cancer-specific survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of treatment on serum testosterone</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term toxicity</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive biomarkers of treatment efficacy</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1048</enrollment>
  <condition>Adenocarcinoma of Prostate</condition>
  <condition>Progression of Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ADT + pelvic RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT for a total duration of 3 years i.e.LHRH agonist or LHRH antagonist +/-Peripheral anti-androgen
Pelvic RT (by IMRT or IGRT protocol):
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT Cabazitaxel: 4 CT cycles
Prostate-only RT (IMRT or IGRT):
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT Cabazitaxel: 4 CT cycles
Pelvic RT (IMRT or IGRT):
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADT + prostate radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen
Prostate-only RT (IMRt or IGRT):
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>Cabazitaxel administered at 25mg/m2 as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles</description>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
    <other_name>jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic radiotherapy</intervention_name>
    <description>Prostate+pelvic RT (2 Gy fractions, 5 times per week):
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
    <arm_group_label>ADT + pelvic RT</arm_group_label>
    <arm_group_label>ADT + cabazitaxel + pelvic RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>prostate radiotherapy</intervention_name>
    <description>Prostate-only RT (2 Gy fractions, 5 times per week):
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy</description>
    <arm_group_label>ADT + Cabazitaxel + prostate RT</arm_group_label>
    <arm_group_label>ADT + prostate radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Any T histologically confirmed adenocarcinoma of the prostate 2) No clinically or
             radiologically suspected metastases, including no enlarged pelvic lymph nodes (&gt; 1 cm
             in small diameter) 3) Gleason score ≥6 4) Meets at least 2 of the following criteria
             for high-risk:

          -  Gleason score ≥ 8

          -  T3 or T4 disease (T3 defined by MRI is acceptable)

          -  Prostate-specific antigen equal or greater than 20 ng/mL 5) No prior treatment for
             prostate cancer except lymph node dissection (patients with pN- and pN+ disease can be
             accrued) or ADT (started up to 6 weeks before randomization).

             6) 18 years ≤ Age≤ 75 years 7) ECOG 0-1 performance status 8) Expected life expectancy
             of more than 10 years 9) Absolute neutrophil count ≥ 1.5 x 109/L 10) Platelets ≥ 100 x
             109/L 11) Hb ≥ 9.0 g/dL 12) Hepatic function: serum bilirubin ≤ 1 ULN; AST and ALT ≤
             2.5 x ULN 13) Renal function (creatinine clearance using the CKD-EPI formula (Chronic
             Kidney Disease Epidemiology group) ≥ 60 mL/min).

             14) Potentially reproductive patients must agree to use an effective contraceptive
             method while on treatment and for 6 months after the final dose of investigational
             product.

             15) Patients must be affiliated to a Social Security System or should fulfill the
             country legislation for clinical trials.

             16) Patients who have received the information sheet and signed the informed consent
             form.

             17) Patients must be willing and able to comply with scheduled visits, treatment plan,
             laboratory tests and other study procedures

        Exclusion Criteria:

          -  1) Patients with other known concurrent severe and/or uncontrolled medical disease
             which could compromise participation in the study, such as:

               1. infection,

               2. cardiac disease such as uncontrolled hypertension, congestive cardiac failure,
                  ventricular arrhythmias, active ischemic heart disease, myocardial infarction
                  within one year, LVEF &gt; grade 2,

               3. uncontrolled diabetes mellitus,

               4. current active hepatic or biliary disease (with exception of subjects with
                  Gilbert's syndrome, asymptomatic gallstones, stable chronic liver disease per
                  investigator assessment),

               5. renal disease,

               6. active GI tract ulceration, malabsorption syndrome, disease significantly
                  affecting gastrointestinal function, or resection of the stomach or small bowel.
                  Subjects with active, uncontrolled ulcerative colitis are also excluded,

               7. known severely impaired lung function (spirometry and DLCO 70% or less of normal
                  and O2 saturation of 88% or less at rest on room air).

                  2) Other prior malignancy within the last 5 years, except basal cell skin cancer
                  3) Physical or psychological condition that would preclude study compliance 4)
                  Hypersensitivity to cabazitaxel (hypersensitivity reaction ≥grade 3), to other
                  taxanes, or to any excipients of the formulation including polysorbate 80 5)
                  Patients with significantly altered mental status prohibiting the understanding
                  of the study or with psychological, familial, sociological or geographical
                  condition potentially hampering compliance with the study protocol and follow-up
                  schedule; those conditions should be discussed with the patient before
                  registration in the trial.

                  6) Patients who received any other investigational drugs within the 30 days prior
                  to the start of cabazitaxel.

                  7) Previous pelvic irradiation that make prostatic irradiation impossible 8)
                  Severe GI disorders precluding pelvic irradiation 9) Patients already included in
                  another therapeutic trial involving an experimental drug 10) Individual deprived
                  of liberty or placed under the authority of a tutor. 11) Concomitant prohibited
                  treatment. Concurrent or planned treatment with strong inhibitors or strong
                  inducers of cytochrome P450 3A4/5 (see Appendix 6). A one week wash-out period is
                  necessary for patients who are already on these treatments
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuelle BOMPAS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO-René Gauducheau - St Herblain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Christophe EYMARD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jean Godinot - Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guilhem ROUBAUD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié - Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe BEUZEBOC, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aline GUILLOT, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie Lucien Neuwirth -ST Priest en Jarez</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claude EL KOURI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Catherine de Sienne - Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank PRIOU, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD VENDEE - La Roche sur Yon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aude FLECHON, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE LEON BERARD - lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor LATORZEFF, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim FIZAZI, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus Grand Paris-Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean BERDAH, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Ste Marguerite - Hyères</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane CULINE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Louis - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie ABADIE-LACOURTOISIE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO - Paul Papin - Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe FOURNERET, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de Chambéry - Chambéry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain GRANDGIRARD, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de Mulhouse - mulhouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique BESSON, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Armoricaine de Radiologie - St Brieuc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loïc MOUREY, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius REGAUD - Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain RUFFION, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier Lyon Sud - Pierre Bénite</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tristan MAURINA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Jean Minoz - Besançon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre CLAVERE, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges - Limoges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Véronique BECKENDORF, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Carles, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron - Barcelone</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riccardo Valdagni, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei tumori - Milan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe RONCHIN, Docteur</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Azuréen de Cancérologie - Mougins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric LECHEVALLIER, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de la conception - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gwenaëlle GRAVIS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli Calmettes - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elise CHAMPEAUX-ORANGE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR Orléans La Source - Orléans</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier ARTIGNAN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Privé Saint-Grégoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne DONEUX, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Générale d'Annecy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thibaud HAASER, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Haut L'Evèque - Pessac</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Youssef TAZI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>STRASBOURG ONCOLOGIE LIBERALE - CLINIQUE SAINTE ANNE - Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane OUDARD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL EUROPEEN GEORGES POMPIDOU - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brigitte LAGUERRE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE EUGENE MARQUIS - Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hakim MAHAMMEDI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE JEAN PERRIN - Clermont Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadine HOUEDE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Nîmes Caremeau - Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaël DEPLANQUE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Paris Saint Joseph - Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjorie BACIUCHKA-PALMARO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Nord Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>yazid BELKACEMI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Henri Mondor - Créteil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mostefa BENNAMOUN, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>L'Institut Mutualiste Montsouris-Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ali HASBINI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur - Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel GROSS, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Privé Clairval - Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bérengère NARCISO RAHARIMANANA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de TOURS Hôpital Bretonneau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carole HELISSEY, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital d'instruction des armées Bégin - St mandé</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta GUIX, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Begoña PEREZ-VALDERRAMA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen del Rocio -Sevilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique GALLARDO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parc Tauli Sabadell Hospital Universitari - Sabadell</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria SAEZ, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Virgen de la Victoria - Malaga</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Montserrat DOMENECH, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Althaia, Xarxa Universitaria i assistencial de Manresa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio VAZQUEZ ESTEVEZ, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lucus Augusti - Lugo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Miguel Anton APARICIO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Teresa Herrera - Coruna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria José MENDEZ VIDAL, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Reina Sofia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar LOPEZ CRIADO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Begoña MELLADO GONZALEZ, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco GOMEZ VEIGA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvador VILLA i FREIXA, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO Badalona - H.U. Germans Trias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel CASTELLANO, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muriel HABIBIAN</last_name>
    <phone>+33(0)176647807</phone>
    <email>m-habibian@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Fizazi, MD, PhD</last_name>
      <phone>33-1-4211-6264</phone>
      <email>fizazi@igr.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pierre Blanchard, Doctor</last_name>
      <email>pierre.blanchard@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2013</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinome</keyword>
  <keyword>prostate</keyword>
  <keyword>relapse</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Androgen Deprivation Therapy</keyword>
  <keyword>Cabazitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

